Scintillation Nanotechnologies, Inc. to exhibit nanoparticle scintillator platform at COMPPÅ Symposium on Membrane Protein Production and Analysis
Scintillation Nanotechnologies, Inc. to exhibit nanoparticle scintillator platform at COMPPÅ Symposium on Membrane Protein Production and Analysis.
Tucson-based Scintillation Nanotechnologies, Inc. was selected in a competitive process to be an exhibitor and sponsor for the second COMPPÅ Symposium on Membrane Protein Production and Analysis in New York. The company – a startup founded to commercialize inventions stemming from research at the University of Arizona – has developed a next generation nanoparticle platform for the detection of radioisotope-labeled compounds directly, and in real-time, in aqueous samples. The unique chemical and physical properties of the company’s aquaSCINTTM and nanoSPATM products provide researchers unprecedented insights into drug uptake, binding, and distribution while saving time, sample costs and reducing costly and dangerous hazardous waste.
“We are pleased to have been selected to exhibit our novel nanoparticle technology at the COMPPÅ Symposium” said Dr. Colleen Janczak, the Head of Research and Development at Scintillation Nanotechnologies, Inc. “COMPPÅ highlights the latest developments in membrane protein structure and function, key elements of the drug discovery process. We are proud to be included and are anxious to share our unique capabilities in the drug discovery process with the researchers and life science partners who attend the COMPPÅ Symposium.”
The 2nd COMPPÅ Symposium on Membrane Protein Production and Analysis will be held at the Roy and Diana Vagelos Education Center, at the Columbia University Medical Center, from June 22-24, 2022. The roster of attendees and presenters, all at the forefront of their respective fields, includes world-renowned scientists, such as keynote speaker Nobel laureate Brian Kobilka from Stanford University. Topics will focus on cutting-edge integral membrane protein production, structural and functional characterization, and computational analyses. For more information about COMPPÅ or the symposium, visit https://www.comppaa.org/
About Scintillation Nanotechnologies, Inc.
Scintillation Nanotechnologies, Inc. is a company dedicated to revolutionizing the sensitivity, selectivity, and resolution of chemical and biological assays through constant innovation in nanoscale radioisotope detectors, enabling breakthrough discoveries in biological, chemical, and environmental systems. It is our mission to bring previously unattainable measurement capabilities to the laboratory, enabling researchers across the full range of scientific endeavor to ask and answer previously impossible research questions, opening the door to discoveries that expand humankind’s knowledge for the betterment of the planet and the human condition
For more information about Scintillation Nanotechnologies, visit https://sntnano.com/.
COMPPÅ (Center on Membrane Protein Production and Analysis) is an NIH NIGMS P41 Biomedical Technology Development and Dissemination (BTDD) Center. COMPPÅ is operated as an independent research center under the direction of Dr. Wayne Hendrickson through the New York Structural Biology Center (NYSBC), a consortium of nine New York biomedical research institutions.
Chief Executive Officer